Page 105 - 南京医科大学学报自然科学版

第43卷第8期 孟亚奇，袁玉刚，吴云慧，等. 外周血预测非小细胞肺癌治疗疗效的研究［J］.
2023年8月 南京医科大学学报（自然科学版），2023，43（8）：1133-1139 ·1139 ·

［8］ RUIZ⁃BAÑOBRE J，ARESES⁃MANRIQUE M C，MOS⁃ are associated with survival in advanced non ⁃ small cell
QUERA⁃MARTÍNEZ J，et al. Evaluation of the lung im⁃ lung cancer undergoing PD⁃1/PD⁃L1 blockade［J］. J Clin
mune prognostic index in advanced non ⁃ small cell lung Med，2019，8（7）：1014-1030
cancer patients under nivolumab monotherapy［J］. Transl ［19］ DIEM S，SCHMID S，KRAPF M，et al. Neutrophil⁃to⁃lym⁃
Lung Cancer Res，2019，8（6）：1078-1085 phocyte ratio（NLR）and platelet ⁃ to ⁃ lymphocyte ratio
［9］ ZHUO M，CHEN H，ZHANG T，et al. The potential pre⁃ （PLR）as prognostic markers in patients with non⁃small
dictive value of circulating immune cell ratio and tumor cell lung cancer（NSCLC）treated with nivolumab［J］.
marker in atezolizumab treated advanced non⁃small cell Lung Cancer，2017，111：176-181
lung cancer patients［J］. Cancer Biomark，2018，22（3）： ［20］ BUDER⁃BAKHAYA K，HASSEL J C. Biomarkers for clin⁃
467-476 ical benefit of immune checkpoint inhibitor treatment ⁃ a
［10］ GANDINI S，MASSI D，MANDALÀ M. PD⁃L1 expression review from the melanoma perspective and beyond［J］.
in cancer patients receiving anti PD⁃1/PD⁃L1 antibodies： Front Immunol，2018，9：1474-1490
a systematic review and meta⁃analysis［J］. Crit Rev Oncol ［21］ PAN Y，YU Y，WANG X，et al. Tumor⁃associated macro⁃
Hematol，2016，100：88-98 phages in tumor immunity［J］. Front Immunol，2020，11：
［11］ MOK T，WU Y L，KUDABA I，et al. Pembrolizumab ver⁃ 583-591
sus chemotherapy for previously untreated，PD ⁃ L1 ⁃ ex⁃ ［22］ LIN Y，XU J，LAN H. Tumor⁃associated macrophages in
pressing，locally advanced or metastatic non ⁃ small ⁃ cell tumor metastasis：biological roles and clinical therapeu⁃
lung cancer（KEYNOTE⁃042）：a randomised，open⁃label， tic applications［J］. J Hematol Oncol，2019，12（1）：76-
controlled，phase 3 trial［J］. Lancet，2019，393（10183）： 91
1819-1830 ［23］ CARRETERO R，SEKTIOGLU I M，GARBI N，et al. Eo⁃
［12］HELLMANN M D，CIULEANU T E，PLUZANSKI A，et sinophils orchestrate cancer rejection by normalizing tu⁃
al. Nivolumab plus ipilimumab in lung cancer with a high mor vessels and enhancing infiltration of CD8（+）T cells
tumor mutational burden［J］. N Engl J Med，2018，378 ［J］. Nat Immunol，2015，16（6）：609-617
（22）：2093-2104 ［24］ GATAULT S，DELBEKE M，DRISS V，et al. IL⁃18 is in⁃
［13］ MARABELLE A，FAKIH M，LOPEZ J，et al. Association volved in eosinophil⁃mediated tumoricidal activity against
of tumour mutational burden with outcomes in patients a colon carcinoma cell line by upregulating LFA ⁃ 1 and
with advanced solid tumours treated with pembrolizumab： ICAM⁃1［J］. J Immunol，2015，195（5）：2483-2492

prospective biomarker analysis of the multicohort，open⁃ ［25］ HOLUB K，BIETE A. Impact of systemic inflammation
label，phase 2 KEYNOTE⁃158 study［J］. Lancet Oncol， biomarkers on the survival outcomes of cervical cancer
2020，21（10）：1353-1365 patients［J］. Clin Transl Oncol，2019，21（7）：836-844
［14］ ZHAO P，LI L，JIANG X，et al. Mismatch repair deficien⁃ ［26］ ROSNER S，KWONG E，SHOUSHTARI A N，et al. Pe⁃
cy/microsatellite instability⁃high as a predictor for anti⁃ ripheral blood clinical laboratory variables associated
PD⁃1/PD⁃L1 immunotherapy efficacy［J］. J Hematol On⁃ with outcomes following combination nivolumab and ipili⁃
col，2019，12（1）：54-67 mumab immunotherapy in melanoma［J］. Cancer Med，
［15］ SCOGNAMIGLIO G，De CHIARA A，Di BONITO M，et 2018，7（3）：690-697
al. Variability in immunohistochemical detection of pro⁃ ［27］ REINA⁃CAMPOS M，SCHARPING N E，GOLDRATH A
grammed death ligand 1（PD ⁃ L1）in cancer tissue types W. CD8（+）T cell metabolism in infection and cancer［J］.
［J］. Int J Mol Sci，2016，17（5）：790-800 Nat Rev Immunol，2021，21（11）：718-738
+
［16］ HO W J，YARCHOAN M，HOPKINS A，et al. Association ［28］ LI F，LI C，CAI X，et al. The association between CD8 tu⁃
between pretreatment lymphocyte count and response to mor⁃infiltrating lymphocytes and the clinical outcome of
PD1 inhibitors in head and neck squamous cell carcino⁃ cancer immunotherapy：a systematic review and meta ⁃
mas［J］. J Immunother Cancer，2018，6（1）：84-91 analysis［J］. EClinicalMedicine，2021，41：2589-2600
［17］ AMERATUNGA M，CHÉNARD⁃POIRIER M，MORENO ［29］ MIAO K，ZHANG X，WANG H，et al. Peripheral blood
C I，et al. Neutrophil⁃lymphocyte ratio kinetics in patients lymphocyte subsets predict the efficacy of immune check⁃
with advanced solid tumours on phase I trials of PD⁃1/PD⁃ point inhibitors in non⁃small cell lung cancer［J］. Front
L1 inhibitors［J］. Eur J Cancer，2018，89：56-63 Immunol，2022，13：912-921
［18］ HUEMER F，LANG D，WESTPHAL T，et al. Baseline ab⁃ ［收稿日期］ 2023-01-19
solute lymphocyte count and ECOG performance score （本文编辑：唐 震）